Abstract
To date, a comprehensive analysis of patterns of failure and predictors of bone metastasis (BM) and prostate cancer specific mortality (PCSM) following biochemical failure (BF) has not been performed for patients with PC treated with EBRT in the dose escalation era.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
